サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1733925

肝細胞増殖因子（HGFs）の世界市場

Hepatocyte Growth Factors (HGFs)

出版日
ページ情報
英文 384 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
肝細胞増殖因子（HGFs）の世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 384 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝細胞増殖因子（HGFs）の世界市場は2030年までに9,920万米ドルに達する見込み

2024年に7,270万米ドルと推定される肝細胞増殖因子（HGFs）の世界市場は、分析期間2024-2030年にCAGR 5.3%で成長し、2030年には9,920万米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるフェーズIII／進行中のHGFは、CAGR6.7％を記録し、分析期間終了までに3,580万米ドルに達すると予想されます。フェーズⅡ／承認済みHGFsセグメントの成長率は、分析期間中CAGR 3.7％と推定されます。

米国市場は推定1,980万米ドル、中国はCAGR 8.6％で成長予測

米国の肝細胞増殖因子（HGFs）市場は、2024年には1,980万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに予測市場規模2,010万米ドルに達すると予測され、分析期間2024-2030年のCAGRは8.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.3％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の肝細胞増殖因子（HGFs）市場- 主要動向と促進要因のまとめ

なぜ肝細胞増殖因子が再生医療で注目されているのか？

肝細胞増殖因子（HGFs）は、様々な上皮細胞や内皮細胞に対する強力な分裂促進作用、形態形成作用、抗アポトーシス作用により、再生医療の分野で重要な成分として浮上しています。元来、HGFは肝臓再生の役割のために発見されたが、現在では、腎臓、肺、神経系の修復を含む、より広範な組織修復と臓器再生の機能のために認識されています。細胞増殖、血管新生、および抗線維化活性を促進するHGFの能力は、慢性肝疾患、急性臓器損傷、および代謝性疾患の治療に大いに関係しています。

肝不全、非アルコール性脂肪性肝疾患（NAFLD）、および肝炎の発生率が世界的に増加するにつれ、HGFは、特に肝移植の適応とならない患者に対する潜在的な治療ソリューションとして支持を集めています。これと並行して、幹細胞研究や組織工学における細胞ベースの治療法の成長と生物学的に活性な分子への需要が、HGFへの関心をさらに加速しています。これらの成長因子はまた、がん治療、特に肝細胞がんのバイオマーカーや補助療法としても研究されています。

バイオテクノロジーの進歩はHGFに基づく治療薬をどのように強化するのか？

バイオテクノロジーの革新は、HGFの産生、送達、調査方法を再形成しつつあります。組換えDNA技術は、研究および治療応用のための生物活性ヒトHGFの大量生産を可能にしました。タンパク質の精製、安定性の向上、生物工学の進歩は、生体内におけるHGFの薬物動態と標的送達を改善しています。研究開発者は現在、全身的副作用を最小限に抑えつつ、組織特異的活性化を増強するHGF模倣体やHGF遺伝子治療ベクターを開発しています。

ナノ粒子デリバリーシステム、ハイドロゲル、足場をベースとしたバイオマテリアルもまた、傷害部位にHGFを局在させ、その放出を持続させることで、治療効果を最大化するために使用されています。これと並行して、HGFsを分泌する間葉系幹細胞（MSCs）を用いた細胞ベースのシステムが、前臨床試験や初期段階の臨床試験でテストされています。このようなデリバリー技術革新は、創傷治癒、心血管修復、神経再生など、肝疾患以外にもHGFの新たな用途を開拓しつつあります。

HGFの需要を促進している臨床セグメントと研究分野は？

肝疾患治療は、特に慢性肝線維症、肝硬変、急性肝障害など、HGF応用の最大の臨床セグメントであり続けています。研究機関や製薬会社は、移植後の肝再生や抗線維化薬との併用におけるHGFの役割を評価する試験を実施しています。腎臓学と神経学は新たな重点分野であり、HGFは腎障害回復、脊髄修復、脳卒中リハビリテーションへの応用の可能性が研究されています。

地理的には、北米と日本が、強力な研究開発インフラ、支持的な規制環境、肝疾患の大規模な患者プールを背景に、HGF市場をリードしています。欧州は、トランスレーショナルリサーチへの資金提供やバイオテクノロジー企業との提携を通じてその足跡を拡大しつつあり、中国と韓国は再生医療パイプラインにますます積極的になりつつあります。産学連携と政府補助金は、HGF研究を臨床治療へと移行させる上で重要な役割を果たしています。

肝細胞増殖因子市場の成長はいくつかの要因に牽引されている...

肝細胞増殖因子市場の成長は、バイオ医薬品の技術革新、再生医療応用の拡大、肝臓や組織修復におけるアンメット・クリニカル・ニーズと結びついたいくつかの要因によって牽引されています。リコンビナントタンパク質合成、標的デリバリーメカニズム、組織工学的プラットフォームなどの技術的進歩により、HGFに基づく治療法はより実行可能でスケーラブルなものとなっています。幹細胞治療、3Dバイオプリンティング、オルガノイド開発と組み合わせたHGFの利用が増加しており、その関連性はさらに加速しています。

最終用途の観点からは、慢性肝疾患の有病率の増加と臓器移植の利用可能性の限界とが相まって、代替再生治療に対する強い需要が生まれています。特にHGFアナログや模倣品に対する臨床試験への継続的な投資は、治療の展望を広げています。さらに、精密医療や個別化医療への関心の高まりは、HGFを次世代生物学的治療薬の主な分子として位置づけ、学術研究と商業的医薬品開発の両領域で力強い成長を示しています。

セグメント

タイプ（フェーズ III/進行中タイプ,フェーズ II/承認済みタイプ,フェーズ II/進行中タイプ,フェーズ Iタイプ,前臨床タイプ）;アプリケーション（がん領域アプリケーション,循環器領域アプリケーション,中枢神経系アプリケーション,血液疾患アプリケーション）;エンドユーザー（製薬&バイオテクノロジー企業エンドユーザー, CMO &CDMOエンドユーザー,研究センター&学術機関エンドユーザー）。

調査対象企業の例（注目の42社）

  • Bio-Techne Corporation
  • GenScript Biotech Corporation
  • Helixmith Co., Ltd.
  • Kringle Pharma, Inc.
  • Miltenyi Biotec GmbH
  • Quanterix Corporation
  • RayBiotech, Inc.
  • REPROCELL Inc.
  • Sino Biological Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33919

Global Hepatocyte Growth Factors (HGFs) Market to Reach US$99.2 Million by 2030

The global market for Hepatocyte Growth Factors (HGFs) estimated at US$72.7 Million in the year 2024, is expected to reach US$99.2 Million by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Phase III / Ongoing HGFs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$35.8 Million by the end of the analysis period. Growth in the Phase II / Approved HGFs segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.8 Million While China is Forecast to Grow at 8.6% CAGR

The Hepatocyte Growth Factors (HGFs) market in the U.S. is estimated at US$19.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$20.1 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Hepatocyte Growth Factors (HGFs) Market - Key Trends & Drivers Summarized

Why Are Hepatocyte Growth Factors Receiving Heightened Attention in Regenerative Medicine?

Hepatocyte Growth Factors (HGFs) are emerging as critical components in the field of regenerative medicine due to their potent mitogenic, morphogenic, and anti-apoptotic effects on a variety of epithelial and endothelial cells. Originally discovered for their liver regeneration role, HGFs are now recognized for their broader tissue repair and organ regeneration functions, including kidney, lung, and nervous system repair. Their capacity to promote cell proliferation, angiogenesis, and anti-fibrotic activity makes them highly relevant in the treatment of chronic liver diseases, acute organ injury, and metabolic disorders.

As the incidence of liver failure, non-alcoholic fatty liver disease (NAFLD), and hepatitis increases globally, HGFs are gaining traction as a potential therapeutic solution, particularly for patients who are not eligible for liver transplantation. In parallel, the growth of cell-based therapies and the demand for biologically active molecules in stem cell research and tissue engineering are further accelerating interest in HGFs. These growth factors are also being explored as biomarkers and adjunct therapies in cancer treatment, particularly hepatocellular carcinoma.

How Are Advances in Biotechnology Enhancing HGF-Based Therapeutics?

Biotechnology innovations are reshaping how HGFs are produced, delivered, and studied. Recombinant DNA technologies have enabled the mass production of bioactive human HGF for research and therapeutic applications. Advances in protein purification, stability enhancement, and bioengineering are improving the pharmacokinetics and targeted delivery of HGFs in vivo. Researchers are now developing HGF mimetics and HGF gene therapy vectors that enhance tissue-specific activation while minimizing systemic side effects.

Nanoparticle delivery systems, hydrogels, and scaffold-based biomaterials are also being used to localize and sustain the release of HGFs at injury sites, maximizing therapeutic efficacy. In parallel, cell-based systems using mesenchymal stem cells (MSCs) that secrete HGFs are being tested in preclinical and early-stage clinical trials. These delivery innovations are opening up new applications for HGFs beyond hepatology, including in wound healing, cardiovascular repair, and neurological regeneration.

Which Clinical Segments and Research Fields Are Fueling Demand for HGFs?

Liver disease treatment remains the largest clinical segment for HGF applications, particularly in chronic liver fibrosis, cirrhosis, and acute liver injury. Research institutes and pharmaceutical companies are conducting trials to evaluate HGF’s role in liver regeneration post-transplant and in combination with antifibrotic drugs. Nephrology and neurology are emerging focus areas, with HGF studied for potential applications in kidney injury recovery, spinal cord repair, and stroke rehabilitation.

Geographically, North America and Japan lead the HGF market, given their strong R&D infrastructure, supportive regulatory environments, and large patient pools for liver disease. Europe is expanding its footprint through translational research funding and biotech partnerships, while China and South Korea are becoming increasingly active in regenerative medicine pipelines. Academic-industry collaborations and government grants are playing a crucial role in translating HGF research into clinical therapies.

The Growth in the Hepatocyte Growth Factors Market Is Driven by Several Factors…

The growth in the hepatocyte growth factors market is driven by several factors tied to biopharmaceutical innovation, expanding regenerative medicine applications, and unmet clinical needs in liver and tissue repair. Technological advancements in recombinant protein synthesis, targeted delivery mechanisms, and tissue-engineered platforms have made HGF-based therapies more viable and scalable. The growing use of HGF in combination with stem cell therapy, 3D bioprinting, and organoid development is further accelerating its relevance.

From an end-use standpoint, increasing prevalence of chronic liver diseases, coupled with limited organ transplant availability, is creating strong demand for alternative regenerative treatments. Continued investment in clinical trials, particularly for HGF analogs and mimetics, is widening the therapeutic landscape. Moreover, rising interest in precision and personalized medicine is positioning HGFs as key molecules in next-generation biological therapeutics, signaling robust growth across both academic research and commercial drug development domains.

SCOPE OF STUDY:

The report analyzes the Hepatocyte Growth Factors (HGFs) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type, Preclinical Type); Application (Oncology Application, Cardiovascular Application, Central Nervous System Application, Hematological Disorders Application); End-User (Pharma & Biotech Companies End-User, CMOs & CDMOs End-User, Research Centers & Academic Institutes End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Bio-Techne Corporation
  • GenScript Biotech Corporation
  • Helixmith Co., Ltd.
  • Kringle Pharma, Inc.
  • Miltenyi Biotec GmbH
  • Quanterix Corporation
  • RayBiotech, Inc.
  • REPROCELL Inc.
  • Sino Biological Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Hepatocyte Growth Factors (HGFs) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Liver Disorders and Cirrhosis Propels Demand for Hepatocyte Growth Factor-Based Therapies
    • Growth in Regenerative Medicine Research Drives Exploration of HGFs for Liver Tissue Repair and Cell Therapy
    • Advancements in Stem Cell and Gene Therapy Platforms Support Use of HGFs in Targeted Liver Regeneration
    • Increased Clinical Focus on Hepatic Fibrosis and Fatty Liver Disease Highlights the Therapeutic Role of HGFs
    • Government Funding and Academic Research Programs Boost Innovation in HGF-Based Drug Development
    • Pharmaceutical R&D Collaboration Expands Pipelines Featuring HGFs for Liver and Organ Regeneration
    • Promising Preclinical and Phase I Trial Outcomes Strengthen Commercial Potential of HGF Therapeutics
    • Expansion of Biotechnology Platforms Enhances Scalable Production of Recombinant HGFs
    • Liver Transplant Alternatives and Bridging Therapies Drive Clinical Demand for HGF-Based Interventions
    • Growing Use of HGFs in Hepatocyte Culture and Drug Toxicity Screening Supports In Vitro Applications
    • Rise in Acute Liver Injury Cases Linked to Drug Reactions and Toxins Increases Market Relevance of HGFs
    • Interest in Combination Therapies with Anti-Inflammatory and Anti-Fibrotic Agents Expands Therapeutic Scope
    • Biopharmaceutical Innovation in PEGylated and Long-Acting HGFs Improves Dosing and Bioavailability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatocyte Growth Factors (HGFs) Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatocyte Growth Factors (HGFs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Phase III / Ongoing Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Phase III / Ongoing Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Phase III / Ongoing Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase II / Approved Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phase II / Approved Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phase II / Approved Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phase II / Ongoing Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phase II / Ongoing Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Phase II / Ongoing Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Phase I Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Phase I Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Phase I Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Preclinical Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Preclinical Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Preclinical Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharma & Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pharma & Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for CMOs & CDMOs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for CMOs & CDMOs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for CMOs & CDMOs End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research Centers & Academic Institutes End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Research Centers & Academic Institutes End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Research Centers & Academic Institutes End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Central Nervous System Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Central Nervous System Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Central Nervous System Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Hematological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • JAPAN
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • CHINA
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • EUROPE
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Hepatocyte Growth Factors (HGFs) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • FRANCE
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • GERMANY
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • INDIA
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030
  • AFRICA
    • Hepatocyte Growth Factors (HGFs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Hepatocyte Growth Factors (HGFs) by Type - Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Type - Percentage Breakdown of Value Sales for Phase III / Ongoing Type, Phase II / Approved Type, Phase II / Ongoing Type, Phase I Type and Preclinical Type for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Hepatocyte Growth Factors (HGFs) by End-user - Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, CMOs & CDMOs End-User and Research Centers & Academic Institutes End-User for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Hepatocyte Growth Factors (HGFs) by Application - Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Hepatocyte Growth Factors (HGFs) by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Application, Central Nervous System Application and Hematological Disorders Application for the Years 2015, 2025 & 2030

IV. COMPETITION